研究者詳細 - 満間　綾子

A Prospective Cohort Study Exploring the Effect of Lenvatinib Planned Drug Holidays in Treatment of Differentiated Thyroid Cancer

Tahara, M; Takami, H; Ito, Y; Okamoto, T; Sugitani, I; Sugino, K; Takahashi, S; Takeyama, H; Tsutsui, H; Hara, H; Mitsuma, A; Yamashita, H; Ohashi, Y; Imai, T

THYROID 34 巻 ( 5 ) 頁： 566 - 574 2024年5月

記述言語：英語出版者・発行元：Thyroid

Background: Although lenvatinib is the preferred treatment for unresectable radioactive iodine-refractory differentiated thyroid cancer (RR-DTC), this agent exerts considerable toxicities, which can lead to frequent dose interruptions and modifications. The adoption of planned drug holidays has been recently suggested as one means of minimizing or avoiding these severe adverse events. Our retrospective study demonstrated that planned drug holidays appear to be a promising strategy for continuing of lenvatinib. However, the benefits of planned drug holidays in a prospective study have yet to be clarified. Here, we investigated the impact of planned drug holidays on clinical outcomes in patients treated with lenvatinib in the COLLECT study. Methods: In COLLECT, a prospective observational study, patients with RR-DTC were treated with lenvatinib in a real-world clinical setting. Lenvatinib was administered orally at a dose of 24 mg daily. Dose modification for toxicities was permitted. Furthermore, planned drug holidays were allowed to avoid severe or intolerable toxicities. The present post hoc analysis focused on evaluating the impact of planned drug holidays on clinical outcomes, including overall survival (OS), time to treatment failure (TTF), time to failure strategy (TFS), and progression-free survival (PFS), in patients in the COLLECT study who were treated with lenvatinib. Results: In total, 262 patients were included. Of the 253 patients evaluable for efficacy, 73 undertook a planned drug holiday at the discretion of the attending physician. OS, TTF, TFS, and PFS were significantly longer in patients who used a planned drug holiday than in those who did not. The planned drug holiday group demonstrated notable clinical outcomes, with a 1-year OS of 95.8% and a 1-year PFS of 94.5%. Moreover, planned drug holidays demonstrated a clinically meaningful advantage in clinical outcomes. The planned drug holiday group had a significantly longer duration of administration at a dose of ≥10 mg. Conclusions: Planned drug holidays for lenvatinib were associated with significantly improved clinical outcomes compared to daily oral administration. Further investigation of the optimal treatment schedule for lenvatinib is warranted. Clinical Trial Registration: UMIN000022243.

DOI： 10.1089/thy.2023.0553

A phase I study of LCL161, a novel oral pan-inhibitor of apoptosis protein (IAP) antagonist, in Japanese patients with advanced solid tumors

特集化学療法誘発性末梢神経障害(CIPN)　～しびれに悩む患者に,なにができるか～ Ⅰ.CIPNとは CIPNの機序

満間綾子

がん看護 28 巻 ( 6 ) 頁： 533 - 536 2023年7月

Analysis of the COLLECT Study - Efficacy and safety of lenvatinib in differentiated thyroid cancer

Iwasaki Hiroyuki, Takami Hiroshi, Yasuhiro Ito, Takahiro Okamoto, Iwao Sugitani, Kiminori Sugino, Shunji Takahashi, Hiroshi Takeyama, Hidemitsu Tutui, Hisato Hara, Ayako Mitsuma, Hiroyuki Yamashita, Yasuo Ohashi, Takeru Shiroiwa, Tuneo Imai, Makoto Tahara

ANNALS OF ONCOLOGY 33 巻頁： S466 - S467 2022年7月

Morita Sachi, Minami Hironobu, Mitsuma Ayako, Toyoda Masanori, Kiyota Naomi, Ando Yuichi

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 2022年1月

記述言語：日本語出版者・発行元：Asia-Pacific Journal of Clinical Oncology

Introduction: LCL161 is a novel oral pan-inhibitor of apoptosis protein (IAP) antagonist. LCL161 enhances paclitaxel activity in cell lines and xenograft models. A phase I study of LCL161 combined with paclitaxel for the treatment of Japanese patients with advanced solid tumors was conducted. Methods: Each patient received oral LCL161 in a single weekly dose on days 1, 8, and 15 of a 21-day treatment cycle. In the second cycle, patients received a combination treatment with weekly paclitaxel (80 mg/m2) whenever possible. A Bayesian logistic regression model by escalation with the overdose control principle was used. Results: Nine patients were treated with LCL161 at a dose of 600 mg (five patients) or 1200 mg (four patients). Seven patients were treated with LCL161 plus paclitaxel, and two patients received only LCL161 monotherapy. Because this study was terminated early due to a change in the LCL161 development strategy, the maximum tolerated dose (MTD) was not determined. One patient treated with LCL161 monotherapy at a dose of 1200 mg experienced dose limitind toxicity (grade 3 maculopapular rash). Another patient died on day 86 of bacterial pneumonia, which was suspected to be related to the study treatment. The most common serious adverse events were infections and infestations (n = 3). Conclusion: The present study suggests that the risk of infection may increase when LCL161 is combined with paclitaxel, but other conclusions about the MTD, pharmacokinetic profile, and preliminary activity of the combination of LCL161 plus paclitaxel were not drawn.

DOI： 10.1111/ajco.13744

Chemotherapy for Older Patients with Cancer

Mitsuma A., Ando Y.

Gan to kagaku ryoho. Cancer & chemotherapy 49 巻 ( 1 ) 頁： 13 - 18 2022年1月

出版者・発行元：Gan to kagaku ryoho. Cancer & chemotherapy

Older patients with cancer are different physically, psycho-spirituality, and socio-economically, and when considering the indications for chemotherapy and other drug therapies for cancer, it is important to comprehensively assess their condition and risk using geriatric assessment(GA). Multidisciplinary team-based approach is essential to address impaired domains that are found by GA. The G8 screening is useful tool for screening the GA candidates. In recent years, there have been increasing opportunities that older patients with cancer who receive immunotherapy with immune checkpoint inhibitors. There is no consensus on the treatment and management of immune-related adverse events(irAEs)specific to older patients, and therefore it is important to adhere to an evidence-based approach.

Collision Tumors of Gastric Adenocarcinoma and Mucosa-associated Lymphoid Tissue Lymphoma

Drug-induced thrombocytopenia associated with trastuzumab in a patient with HER2-positive recurrent gastric cancer

Takano Yuko, Furune Satoshi, Miyai Yuki, Morita Sachi, Inoue Megumi, Shimokata Tomoya, Sugishita Mihoko, Mitsuma Ayako, Maeda Osamu, Ando Yuichi

INTERNATIONAL CANCER CONFERENCE JOURNAL 11 巻 ( 1 ) 頁： 67 - 70 2022年1月

Vitiligo and tumor response in a patient with amelanotic melanoma undergoing nivolumab treatment

Furune Satoshi, Kondo Chiaki, Takano Yuko, Shimokata Tomoya, Sugishita Mihoko, Mitsuma Ayako, Maeda Osamu, Ando Yuichi

INTERNATIONAL CANCER CONFERENCE JOURNAL 11 巻 ( 1 ) 頁： 46 - 48 2022年1月

[Chemotherapy for Older Patients with Cancer].

Mitsuma A, Ando Y

Gan to kagaku ryoho. Cancer & chemotherapy 49 巻 ( 1 ) 頁： 13 - 18 2022年1月

Vitiligo and tumor response in a patient with amelanotic melanoma undergoing nivolumab treatment (Oct, 10.1007/s13691-021-00515-w, 2021)

Furune Satoshi, Kondo Chiaki, Takano Yuko, Shimokata Tomoya, Sugishita Mihoko, Mitsuma Ayako, Maeda Osamu, Ando Yuichi

INTERNATIONAL CANCER CONFERENCE JOURNAL 11 巻 ( 1 ) 頁： 49 - 49 2022年1月

A case of recurrent gastric cancer with drug-induced immune thrombocytopenia caused by trastuzumab

Takano Yuko, Furune Satoshi, Morita Sachi, Inoue Megumi, Shimokata Tomoya, Sugishita Mihoko, Mitsuma Ayako, Osamu Maeda, Ando Yuichi

ANNALS OF ONCOLOGY 32 巻頁： S354 - S354 2021年7月

Planned drug holiday in a cohort study exploring the effect of lenvatinib on differentiated thyroid cancer.

Tahara Makoto, Takami Hiroshi, Ito Yasuhiro, Okamoto Takahiro, Sugitani Iwao, Sugino Kiminori, Takahashi Shunji, Takeyama Hiroshi, Tsutsui Hidemitsu, Hara Hisato, Mitsuma Ayako, Yamashita Hiroyuki, Ohashi Yasuo, Imai Tsuneo

JOURNAL OF CLINICAL ONCOLOGY 39 巻 ( 15 ) 2021年5月

Kobayashi Kenichi, Furukawa Kazuhiro, Ishikawa Eri, Mitsuma Ayako, Funasaka Kohei, Kakushima Naomi, Furune Satoshi, Ito Nobuhito, Wada Hirotaka, Hirose Takashi, Muroi Koichi, Suzuki Tomohiko, Suzuki Takahiro, Hida Emiko, Hirai Keiko, Shibata Hiroyuki, Koya Toshinari, Nakamura Masanao, Kawashima Hiroki, Miyahara Ryoji, Fujishiro Mitsuhiro

INTERNAL MEDICINE 60 巻 ( 15 ) 頁： 2419 - 2424 2021年

記述言語：日本語出版者・発行元：一般社団法人日本内科学会

A 65-year-old woman with a history of treatment for splenic marginal zone B-cell lymphoma and gastric mucosa-associated lymphoid tissue (MALT) lymphoma underwent esophagogastroduodenoscopy. A reddish elevated lesion was found in the fundus of the stomach. On image-enhanced endoscopy, several findings, such as glandular structures of varying sizes suggesting well-differentiated adenocarcinoma, pruned blood vessels, and dilated blood vessels in deeper mucosa suggesting MALT lymphoma, were observed. The final pathological diagnosis after surgical resection was collision tumors of well-differentiated adenocarcinoma and MALT lymphoma. The features of both tumors could be observed simultaneously with image-enhanced endoscopy.

DOI： 10.2169/internalmedicine.6124-20

Quantitative assessment of chemotherapy-induced peripheral neurotoxicity using a point-of-care nerve conduction device

抗がん薬曝露対策のTip and Trick―Beyond the Guideline 「メディカルサーベイランス」

満間綾子

月刊薬事 vol.61 No.5 巻頁： 74 - 78 2019年

3.抗がん薬の臨床薬理学～分子標的薬とその心毒性～

満間綾子, 安藤雄一

医薬ジャーナル vol.54 No.12 巻 2018年

Matsuoka, A; Mitsuma, A; Maeda, O; Kajiyama, H; Kiyoi, H; Kodera, Y; Nagino, M; Goto, H; Ando, Y

CANCER SCIENCE 107 巻 ( 10 ) 頁： 1453 - 1457 2016年10月

記述言語：英語出版者・発行元：Wiley

<jats:p>Chemotherapy‐induced peripheral neurotoxicity (<jats:styled-content style="fixed-case">CIPN</jats:styled-content>) seriously impairs patients’ quality of life cumulatively and dose‐dependently. Because assessment of <jats:styled-content style="fixed-case">CIPN</jats:styled-content> usually depends on patients’ subjective evaluation of symptoms, objective and quantitative measures are needed. We evaluated a point‐of‐care nerve conduction device (<jats:styled-content style="fixed-case">POCD</jats:styled-content>), previously validated for the assessment of diabetic peripheral neuropathy. Sensory nerve action potential (<jats:styled-content style="fixed-case">SNAP</jats:styled-content>) amplitude and sensory nerve conduction velocity (<jats:styled-content style="fixed-case">SNCV</jats:styled-content>) of the sural nerve were measured using a portable, automated <jats:styled-content style="fixed-case">POCD</jats:styled-content> (DPNCheck; NeuroMetrix Inc., Waltham, MA, USA) in patients with a clinical diagnosis of <jats:styled-content style="fixed-case">CIPN</jats:styled-content> of grade 1 or higher. We compared <jats:styled-content style="fixed-case">SNAP</jats:styled-content> and <jats:styled-content style="fixed-case">SNCV</jats:styled-content> among patients with different grades of <jats:styled-content style="fixed-case">CIPN</jats:styled-content> according to the Common Terminology Criteria for Adverse Events. A total of 50 patients (22 men, 28 women; median age, 64 years; grade 1/2/3, 21/18/11) were evaluated. Anticancer drugs responsible for <jats:styled-content style="fixed-case">CIPN</jats:styled-content> were cisplatin in five patients, oxaliplatin in 15, carboplatin in 5, paclitaxel in 16, docetaxel in 14, nab‐paclitaxel in 7, vincristine in 6, and bortezomib in 3. Unadjusted <jats:styled-content style="fixed-case">SNAP</jats:styled-content> was 8.45 ± 3.67 μV (mean ± SD) in patients with grade 1 <jats:styled-content style="fixed-case">CIPN</jats:styled-content>, 5.42 ± 2.68 μV with grade 2, and 2.45 ± 1.52 μV with grade 3. Unadjusted <jats:styled-content style="fixed-case">SNCV</jats:styled-content> was 49.71 ± 4.77 m/s in patients with grade 1 <jats:styled-content style="fixed-case">CIPN</jats:styled-content>, 48.78 ± 6.33 m/s with grade 2, and 44.14 ± 7.31 m/s with grade 3. The adjusted <jats:styled-content style="fixed-case">SNAP</jats:styled-content> after controlling for age significantly differed between each <jats:styled-content style="fixed-case">CTCAE</jats:styled-content> grade (<jats:italic>P</jats:italic> < 0.001, <jats:sc>ancova</jats:sc>). The adjusted <jats:styled-content style="fixed-case">SNCV</jats:styled-content> after controlling for age and height also differed significantly (<jats:italic>P</jats:italic> = 0.027). Differences in the severity of <jats:styled-content style="fixed-case">CIPN</jats:styled-content> could be detected objectively and quantitatively using this <jats:styled-content style="fixed-case">POCD</jats:styled-content>.</jats:p>

DOI： 10.1111/cas.13010

特集:癌化学療法に伴う神経障害性疼痛-最近の研究動向臨床現場からの情報発信:「オキサリプラチンによる末梢神経障害の遺伝的背景」

満間綾子, 安藤雄一

日本薬理学会誌 vol.141 No.2 巻頁： 62 - 65 2013年

特集PK-PDとPGxの最前線「がん分子標的薬のPK-PDとPGx」

満間綾子, 安藤雄一

月刊薬事 vol.52 No.4 巻頁： 39 - 46 2010年

Phase I study of the antiprogrammed cell death-1 Ab spartalizumab (PDR001) in Japanese patients with advanced malignancies

Minami Hironobu, Doi Toshihiko, Toyoda Masanori, Imamura Yoshinori, Kiyota Naomi, Mitsuma Ayako, Shimokata Tomoya, Naito Yoichi, Matsubara Nobuaki, Tajima Takeshi, Tokushige Kota, Ishihara Kae, Cameron Scott, Ando Yuichi

CANCER SCIENCE 112 巻 ( 2 ) 頁： 725 - 733 2021年2月

Chemotherapy for biliary tract cancer: real-world experience in a single institute

Maeda Osamu, Ebata Tomoki, Shimokata Tomoya, Matsuoka Ayumu, Inada-Inoue Megumi, Morita Sachi, Takano Yuko, Urakawa Hiroshi, Miyai Yuki, Sugishita Mihoko, Mitsuma Ayako, Ando Masahiko, Mizuno Takashi, Nagino Masato, Ando Yuichi

NAGOYA JOURNAL OF MEDICAL SCIENCE 82 巻 ( 4 ) 頁： 725 - 733 2020年11月

Solitary fibrous tumor/hemangiopericytoma treated with temozolomide plus bevacizumab: a report of four cases and literature review

Maeda Osamu, Ohka Fumiharu, Maesawa Satoshi, Matsuoka Ayumu, Shimokata Tomoya, Mitsuma Ayako, Urakawa Hiroshi, Nakamura Shota, Shimoyamas Yoshic, Nakaguro Masato S., Wakabayashi Toshihiko, Ando Yuichi

NAGOYA JOURNAL OF MEDICAL SCIENCE 82 巻 ( 4 ) 頁： 631 - 644 2020年11月

Clinical value of serum bone resorption markers for predicting clinical outcomes after use of bone modifying agents in metastatic bone tumors: A prospective cohort study

Urakawa Hiroshi, Ando Yuichi, Hase Tetsunari, Kikumori Toyone, Arai Eisuke, Maeda Osamu, Mitsuma Ayako, Sugishita Mihoko, Shimokata Tomoya, Ikuta Kunihiro, Ishiguro Naoki, Nishida Yoshihiro

INTERNATIONAL JOURNAL OF CANCER 146 巻 ( 12 ) 頁： 3504 - 3515 2020年6月

Detection of bacteria in blood circulation in patients receiving cancer chemotherapy

Ota Akiko, Morita Sachi, Matsuoka Ayumu, Shimokata Tomoya, Maeda Osamu, Mitsuma Ayako, Yagi Tetsuya, Asahara Takashi, Ando Yuichi

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY 25 巻 ( 1 ) 頁： 210 - 215 2020年1月

A longitudinal tracking and quantitative assessment of paclitaxel-induced peripheral neurotoxicity

Matsuoka A., Mitsuma A., Maeda O., Tsunoda N., Kikumori T., Ando Y.

ANNALS OF ONCOLOGY 30 巻 2019年10月

Phase I study of spartalizumab (PDR001), an anti-PD1 mAb, in Japanese patients with advanced malignancies

Ando Yuichi, Doi Toshihiko, Mitsuma Ayako, Mizutani Takefumi, Toyoda Masanori, Imamura Yoshinori, Kiyota Naomi, Naito Yoichi, Matsubara Nobuaki, Ishihara Kae, Tajima Takeshi, Tokushige Kota, Cameron Scott, Minami Hironobu

ANNALS OF ONCOLOGY 29 巻頁： . 2018年10月

Outpatient chemotherapy for patients with unresectable or metastatic bone sarcomas

Urakawa Hiroshi, Nishida Yoshihiro, Mitsuma Ayako, Maeda Osamu, Sugishita Mihoko, Shimokata Tomoya, Mizutani Takeshi, Arai Eisuke, Ikuta Kunihiro, Hamada Shunsuke, Ota Takehiro, Ishiguro Naoki, Ando Yuichi

ANNALS OF ONCOLOGY 29 巻頁： . 2018年10月

A longitudinal study of a new point-of-care nerve conduction device for quantitative assessment of chemotherapy-induced peripheral neurotoxicity

Matsuoka A., Maeda O., Mitsuma A., Uehara K., Nakayama G., Nagino M., Kodera Y., Ando Y.

ANNALS OF ONCOLOGY 29 巻頁： . 2018年10月

Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First-Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG-1201 Study)

Nakayama Goro, Mitsuma Ayako, Sunagawa Yuki, Ishigure Kiyoshi, Yokoyama Hiroyuki, Matsui Takanori, Nakayama Hiroshi, Nakata Kazuhiko, Ishiyama Akiharu, Asada Takahiro, Umeda Shinichi, Ezaka Kazuhiro, Hattori Norifumi, Takami Hideki, Kobayashi Daisuke, Tanaka Chie, Kanda Mitsuro, Yamada Suguru, Koike Masahiko, Fujiwara Michitaka, Fujii Tsutomu, Murotani Kenta, Ando Yuichi, Kodera Yasuhiro

ONCOLOGIST 23 巻 ( 8 ) 頁： 919 - 927 2018年8月

Real-world experience with FOLFIRINOX and gemcitabine plus nab-paclitaxel in the treatment of pancreatic cancer in Japan

Maeda O., Yokoyama Y., Yamaguchi J., Ota A., Matsuoka A., Morita S., Inoue M., Mizutani T., Shimokata T., Urakawa H., Mitsuma A., Nagino M., Ando Y.

ANNALS OF ONCOLOGY 28 巻頁： 69-69 2017年11月

Erratum: High-dose chemotherapy with autologous peripheral blood stem cell transplantation for choriocarcinoma: A case report and literature review.

Yamamoto E, Niimi K, Fujikake K, Nishida T, Murata M, Mitsuma A, Ando Y, Kikkawa F

Molecular and clinical oncology 7 巻 ( 3 ) 頁： 510 2017年9月

Assessment of left ventricular diastolic function during trastuzumab treatment in patients with HER2-positive breast cancer

Honda Kazunori, Takeshita Kyosuke, Murotani Kenta, Mitsuma Ayako, Hayashi Hironori, Tsunoda Nobuyuki, Kikumori Toyone, Murohara Toyoaki, Ando Yuichi

BREAST CANCER 24 巻 ( 2 ) 頁： 312 - 318 2017年3月

Salient features and outline of the joint Japanese guidelines for safe handling of cancer chemotherapy drugs

Kanda Kiyoko, Hirai Kazue, Iino Keiko, Nomura Hisanaga, Yasui Hisateru, Kano Taro, Ichikawa Chisato, Hiura Sumiko, Morita Tomoko, Mitsuma Ayako, Komatsu Hiroko

ASIA-PACIFIC JOURNAL OF ONCOLOGY NURSING 4 巻 ( 4 ) 頁： 304 - 312 2017年

High-dose chemotherapy with autologous peripheral blood stem cell transplantation for choriocarcinoma: A case report and literature review

Yamamoto Eiko, Niimi Kaoru, Fujikake Kayo, Nishida Tetsuya, Murata Makoto, Mitsuma Ayako, Ando Yuichi, Kikkawa Fumitaka

MOLECULAR AND CLINICAL ONCOLOGY 5 巻 ( 5 ) 頁： 660 - 664 2016年11月

Pharmacogenetic association between GSTP1 genetic polymorphism and febrile neutropenia in Japanese patients with early breast cancer

Sugishita Mihoko, Imai Tsuneo, Kikumori Toyone, Mitsuma Ayako, Shimokata Tomoya, Shibata Takashi, Morita Sachi, Inada-Inoue Megumi, Sawaki Masataka, Hasegawa Yoshinori, Ando Yuichi

BREAST CANCER 23 巻 ( 2 ) 頁： 195 - 201 2016年3月

Optimal dose of gemcitabine for the treatment of biliary tract or pancreatic cancer in patients with liver dysfunction

Shibata Takashi, Ebata Tomoki, Fujita Ken-ichi, Shimokata Tomoya, Maeda Osamu, Mitsuma Ayako, Sasaki Yasutsuna, Nagino Masato, Ando Yuichi

CANCER SCIENCE 107 巻 ( 2 ) 頁： 168 - 172 2016年2月

Development of "Guidelines for Safe Handling of Cancer Chemotherapy Drugs" in Japan

Hirai Kazue, Kanda Kiyoko, Iino Keiko, Kano Taro, Ichikawa Chisato, Iwamoto Sumiyo, Yasui Hisateru, Mitsuma Ayako, Nomura Hisanaga, Hiura Sumiko, Morita Tomoko, Komatsu Hiroko

CANCER NURSING 39 巻頁： S89 - S90 2016年

Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer

Mukai Hirofumi, Masuda Norikazu, Ishiguro Hiroshi, Mitsuma Ayako, Shibata Takashi, Yamamura Jun, Toi Masakazu, Watabe Aiko, Sarashina Akiko, Uttenreuther-Fischer Martina, Ando Yuichi

CANCER CHEMOTHERAPY AND PHARMACOLOGY 76 巻 ( 4 ) 頁： 739 - 750 2015年10月

Pazopanib monotherapy in a patient with a malignant granular cell tumor originating from the right orbit: A case report

Morita Sachi, Hiramatsu Mariko, Sugishita Mihoko, Gyawali Bishal, Shibata Takashi, Shimokata Tomoya, Urakawa Hiroshi, Mitsuma Ayako, Moritani Suzuko, Kubota Toshinobu, Ichihara Shu, Ando Yuichi

ONCOLOGY LETTERS 10 巻 ( 2 ) 頁： 972 - 974 2015年8月

Postoperative complications following neoadjuvant bevacizumab treatment for advanced colorectal cancer

Yoshioka Yuichiro, Uehara Keisuke, Ebata Tomoki, Yokoyama Yukihiro, Mitsuma Ayako, Ando Yuichi, Nagino Masato

SURGERY TODAY 44 巻 ( 7 ) 頁： 1300 - 1306 2014年7月

Association between severe toxicity of nilotinib and UGT1A1 polymorphisms in Japanese patients with chronic myelogenous leukemia

Shibata Takashi, Minami Yosuke, Mitsuma Ayako, Morita Sachi, Inada-Inoue Megumi, Oguri Tomoyo, Shimokata Tomoya, Sugishita Mihoko, Naoe Tomoki, Ando Yuichi

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY 19 巻 ( 2 ) 頁： 391 - 396 2014年4月

Phase 1 study of pazopanib alone or combined with lapatinib in Japanese patients with solid tumors

Inada-Inoue Megumi, Ando Yuichi, Kawada Kenji, Mitsuma Ayako, Sawaki Masataka, Yokoyama Taro, Sunakawa Yu, Ishida Hiroo, Araki Kazuhiro, Yamashita Keishi, Mizuno Keiko, Nagashima Fumio, Takekura Akiko, Nagamatsu Kazuo, Sasaki Yasutsuna

CANCER CHEMOTHERAPY AND PHARMACOLOGY 73 巻 ( 4 ) 頁： 673 - 683 2014年4月

Phase I dose- escalation study of buparlisib ( BKM120), an oral pan- class I PI3K inhibitor, in Japanese patients with advanced solid tumors

Ando Yuichi, Inada-Inoue Megumi, Mitsuma Ayako, Yoshino Takayuki, Ohtsu Atsushi, Suenaga Naoko, Sato Masahiko, Kakizume Tomoyuki, Robson Matthew, Quadt Cornelia, Doi Toshihiko

CANCER SCIENCE 105 巻 ( 3 ) 頁： 347 - 353 2014年3月

Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors including breast cancer

Masuda N., Mukai H., Ishiguro H., Mitsuma A., Shibata T., Yamamura J., Toi M., Watabe A., Sarashina A., Ebisawa R., Uttenreuther-Fischer M., Ando Y.

CANCER RESEARCH 73 巻 2013年12月

A Phase l study of BYL719, an alpha-isoform selective PI3K inhibitor, in Japanese patients with advanced solid malignancies.

Kogure Yoshihito, Yamada Yasuhide, Saka Hideo, Kitagawa Chiyoe, Iwasa Satoru, Yamamoto Noboru, Aoki Takuji, Kakizume Tomoyuki, Robson Matthew, Quadt Cornelia, Mitsuma Ayako, Shibata Takashi, Ando Yuichi

MOLECULAR CANCER THERAPEUTICS 12 巻 ( 11 ) 2013年11月

A phase I study of tasisulam sodium using an albumin-tailored dose in Japanese patients with advanced solid tumors

Fujiwara Yutaka, Ando Yuichi, Mukohara Toru, Kiyota Naomi, Chayahara Naoko, Mitsuma Ayako, Inada-Inoue Megumi, Sawaki Masataka, Ilaria Robert Jr., Turner P. Kellie, Funai Jumpei, Maeda Kaijiro, Minami Hironobu

CANCER CHEMOTHERAPY AND PHARMACOLOGY 71 巻 ( 4 ) 頁： 991 - 998 2013年4月

[Genetic backgrounds of peripheral neuropathy induced by oxaliplatin].

Mitsuma A, Ando Y

Nihon yakurigaku zasshi. Folia pharmacologica Japonica 141 巻 ( 2 ) 頁： 62 - 5 2013年2月

出版者・発行元：公益社団法人日本薬理学会

がん薬物療法における有害事象として，末梢神経障害を引き起こす薬剤が注目されている．大腸がんのキードラッグであるオキサリプラチン（L-OHP）による末梢神経障害は，蓄積性で用量規定因子である．重篤な場合，治療の遂行が不可能となり，治療効果の障害となる．L-OHPによる末梢神経障害の発現のメカニズムは十分には解明されていない．そこで，シュウ酸（オキサレート）の代謝に関係する2つの酵素であるアラニングリオキシル酸アミノ転移酵素（alanine glyoxylate aminotransferase：AGXT），グリオキシル酸還元酵素-ヒドロキシピルビン酸塩還元酵素（glyoxylate reductase-hydroxypyruvate reductase：GRHPR）の他，解毒酵素であるグルタチオンS-転移酵素（gluthathione S-transferase π1：GSTP 1），および損傷を受けたDNAを修復する除去修復交差相補群1（excision repair cross-complementing gene 1：ERCC 1）の遺伝子多型について，mFOLFOX療法が施行された進行大腸がん患者を対象として末梢神経障害との関連を検討した．その結果，ERCC 1とGSTP 1の遺伝子多型は，L-OHPによる末梢神経障害の発現までの期間と強い関連がみられた．これらの遺伝子多型は末梢神経障害の予測因子であるとともに，その発症機序に関わっている可能性がある．遺伝子多型の頻度やその臨床的意義には人種差が存在する可能性があるため，海外からの研究結果を検証する必要がある．末梢神経障害の精度の高い予測因子が同定されれば，末梢神経障害をきたすL-OHPを避けて治療を行う，あるいは慎重にモニタリングを行うなど，個別化医療の進展に寄与するものと考えられる．

DOI： 10.1254/fpj.141.62

Association between bevacizumab-related hypertension and vascular endothelial growth factor (VEGF) gene polymorphisms in Japanese patients with metastatic colorectal cancer

Morita Sachi, Uehara Keisuke, Nakayama Goro, Shibata Takashi, Oguri Tomoyo, Inada-Inoue Megumi, Shimokata Tomoya, Sugishita Mihoko, Mitsuma Ayako, Ando Yuichi

CANCER CHEMOTHERAPY AND PHARMACOLOGY 71 巻 ( 2 ) 頁： 405 - 411 2013年2月

Phase I dose-escalating study of panobinostat (LBH589) Administered intravenously to Japanese patients with advanced solid tumors

Morita Sachi, Oizumi Satoshi, Minami Hironobu, Kitagawa Koichi, Komatsu Yoshito, Fujiwara Yutaka, Inada Megumi, Yuki Satoshi, Kiyota Naomi, Mitsuma Ayako, Sawaki Masataka, Tanii Hiromi, Kimura Junko, Ando Yuichi

INVESTIGATIONAL NEW DRUGS 30 巻 ( 5 ) 頁： 1950 - 1957 2012年10月

Peripheral neuropathy induced by oxaliplatin is associated with genetic polymorphisms

Mitsuma A., Oguri T., Inada M., Ando Y.

JOURNAL OF NEUROLOGY 259 巻頁： S126 - S126 2012年6月

Pharmacokinetic Study of S-1 in Patients in Whom Inulin Clearance Was Measured

Ando Yuichi, Kawada Kenji, Inada Megumi, Morita Sachi, Mitsuma Ayako, Yasuda Yoshinari, Hiramatsu Mariko, Fujimoto Yasushi, Fujita Ken-ichi

ONCOLOGY 83 巻 ( 1 ) 頁： 38 - 44 2012年

Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genes.

Inada M, Sato M, Morita S, Kitagawa K, Kawada K, Mitsuma A, Sawaki M, Fujita K, Ando Y

International journal of clinical pharmacology and therapeutics 48 巻 ( 11 ) 頁： 729 - 34 2010年11月

The Feasibility Study of Docetaxel in Patients with Anaplastic Thyroid Cancer

Kawada Kenji, Kitagawa Koichi, Kamei Sachi, Nada Megumi, Mitsuma Ayako, Sawaki Masataka, Kikumori Toyone, Fujimoto Yasushi, Arima Hiroshi, Imai Tsuneo, Ando Yuichi

JAPANESE JOURNAL OF CLINICAL ONCOLOGY 40 巻 ( 6 ) 頁： 596 - 599 2010年6月

[Standard chemotherapy of hematological cancers].

Mitsuma A, Naoe T

Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 98 巻 ( 8 ) 頁： 1880 - 6 2009年8月

出版者・発行元：一般社団法人日本内科学会

血液腫瘍における薬物療法は，近年，分子標的治療をはじめとする新規抗がん薬の開発により，従来にない治療成績をもたらしたり，新たな治療手段として生存率の向上に貢献したりすることで大きな進歩を遂げている．しかしながら全身疾患である血液腫瘍では様々な合併症やPS（performance status），臓器機能の低下した高齢患者に対する対応など担当医が直面する問題は多岐にわたる．本稿では内科医が日常臨床で遭遇する可能性の高い代表的な血液腫瘍について概説する．

DOI： 10.2169/naika.98.1880